VBWG HPS. Lancet. 2003;361:2005-16. Gæde P et al. N Engl J Med. 2003;348:383-93. Recent statin trials: Reduction in primary outcome in patients with diabetes.

Slides:

Advertisements

Similar presentations

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.

Advertisements

Atorvastatin in Type 2 diabetics on dialysis: 4D Study 1255 T2DM patients on dialysis for 8.3 mo; 29% with prior MI or revascularization or CHD; 35% CHF;

1 CAMELOT: Study Design A Morbidity and Mortality Study Patients with documented CAD on standard-of-care therapies* (n=1997) Clinical events (morbidity.

1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.

Lipid Disorders and Management in Diabetes

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.

Benefits of intensive multiple risk factor intervention.

Managing the late consequences of CHD: What is the evidence for lipid management Prof Philip Barter The Heart Research Institute Sydney, Australia Slides.

On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs. 2004;9: LaRosa JC et al. N Engl J Med. 2005;352:

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

Cholesterol quintile (mg/dL)

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:

1 Therapies Not Indicated Andrew P. DeFilippis, Ty J. Gluckman, James Mudd, Catherine Campbell, Gregg Fonarow & Roger S. Blumenthal.

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

Randomized, double-blind, multicenter, controlled trial.

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.

Identifying and Treating Patients with Insulin Resistance

The concept of Diabetes & CV risk: A lifetime risk challenge The Clinical Significance of LDL-Cholesterol: No Longer a Hypothesis? John J.P. Kastelein,

Cholesterol Lowering and CV Risk: Meta-analyses. On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs.

Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.

HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.

The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.

VBWG PROactive: Study design Dormandy JA et al. Lancet. 2005;366: Charbonnel B et al. Diabetes Care. 2004;27: Objective: Assess the effects.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Jim McMorran Coventry GP GP with Specialist Interest in Diabetes and.

ASCOT and Steno-2: Aggressive risk reduction benefits two different patient populations *Composite of CV death, nonfatal MI or stroke, revascularization,

Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

4S: Scandinavian Simvastatin Survival Study

Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome

Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial

Diabetes & macrovascular disease. Prevalence of Diabetes: Males Prevalence of raised blood glucose (%) ages 25+, age standardized, ≥ 7 mmol/l or on medication.

FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Clinical Outcomes with Newer Antihyperglycemic Agents

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

TNT: Study Design Treating to New Targets

HOPE: Heart Outcomes Prevention Evaluation study

Pravastatin in Elderly Individuals at Risk of Vascular Disease

AIM HIGH Niacin plus Statin to prevent vascular events

First time a CETP inhibitor shows reduction of serious CV events

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

AIM-HIGH Niacin Plus Statin to Prevent Vascular Events

TNT: Baseline and final LDL cholesterol levels

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

The following slides highlight a report on a presentation at the Late-breaking Trials Session and a Satellite Symposium of the American Heart Association.

Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.

ARISE Trial Aggressive Reduction of Inflammation Stops Events

Cause of death Treatment-arm events, % (n=45 054)

The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

FIELD: Primary outcome

Presentation transcript:

VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes HPSSteno-2 Relative risk reduction (%) P < P = HPS: major coronary event, stroke, or revascularization Steno-2: CV death, nonfatal MI, CABG, PCI, nonfatal stroke, amputation for ischemia, or vascular surgery for PAD

VBWG CARDS: Collaborative AtoRvastatin Diabetes Study design Colhoun HM et al. Diabet Med. 2002;19: Atorvastatin 10 mg Placebo Randomization complete June 2001 Early termination June 2003 Planned completion 2005 Results announced June 2004 Primary outcome: Composite of major coronary events, revascularizations, unstable angina, resuscitated cardiac arrest, and stroke High-risk patients with type 2 diabetes (N = 2838)

VBWG CARDS: Treatment effects on lipids Colhoun HM et al. Lancet. 2004;364: Total-C Average difference 26% 1.4 mmol/L (54 mg/dL) LDL-C Average difference 40% 1.2 mmol/L (46 mg/dL) Years mmol/L Years PlaceboAtorvastatin P <

VBWG CARDS: 37% Reduction in primary outcome Colhoun HM et al. Lancet. 2004;364: Placebo Atorvastatin Years Cumulative hazard (%) 4.75 Placebo 127 events Atorvastatin 83 events Relative risk reduction 37% 95% CI, 17%–52% P = 0.001

VBWG CARDS: Consistent statin effects on components of primary outcome Colhoun HM et al. Lancet. 2004;364: EventPlaceboAtorvastatin Hazard ratio Risk reduction (95% CI) Favors atorvastatin Favors placebo Primary outcome (9.0)83 (5.8) 37% (17–52) P = Acute coronary events 77 (5.5)51 (3.6)36% (9–55) Coronary revascularization 34 (2.4)24 (1.7)31% ( – 16–59) Stroke 39 (2.8)21 (1.5)48% (11–69) n (% randomized)

VBWG ACP recommendations for lipid management in patients with diabetes Lipid-lowering therapy is indicated for secondary prevention in all patients with diabetes and known coronary artery disease Statins are indicated for primary prevention of macrovascular complications in patients with diabetes and other CV risk factors Once statin therapy is initiated, patients should receive at least moderate doses Routine monitoring of liver function or muscle enzymes is not recommended for patients receiving statins, except in specific circumstances Snow V et al. Ann Intern Med. 2004;140:644-9.